Practical Application of Real-World Evidence in Developing Cancer Therapies.
作者信息
Zauderer Marjorie G
机构信息
Weill Cornell Medical College, New York, NY.
出版信息
JCO Clin Cancer Inform. 2019 Jul;3:1-2. doi: 10.1200/CCI.19.00071.
Abstract
摘要
相似文献
1
Practical Application of Real-World Evidence in Developing Cancer Therapies.真实世界证据在癌症治疗开发中的实际应用。
JCO Clin Cancer Inform. 2019 Jul;3:1-2. doi: 10.1200/CCI.19.00071.
2
Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small-cell lung cancer.保持真实：真实世界治疗结果对转移性非小细胞肺癌一线免疫治疗的影响。
Immunotherapy. 2021 Dec;13(18):1453-1456. doi: 10.2217/imt-2021-0237. Epub 2021 Oct 13.
3
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.评估晚期非小细胞肺癌免疫治疗患者结局的真实世界终点的探索性分析
JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.
4
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.美国监管批准后一年接受程序性死亡蛋白 1 抑制剂治疗的转移性非小细胞肺癌患者的真实世界结局。
Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27.
5
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.晚期非小细胞肺癌治疗模式和生存结局的趋势：基于加拿大人群的真实世界分析。
BMC Cancer. 2022 Mar 10;22(1):255. doi: 10.1186/s12885-022-09342-5.
6
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.免疫疗法为基础的一线治疗方案在晚期非小细胞肺癌中的真实世界结局。
Lung Cancer. 2021 Jun;156:41-49. doi: 10.1016/j.lungcan.2021.04.007. Epub 2021 Apr 14.
7
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.葡萄牙免疫治疗时代前晚期非小细胞肺癌的真实世界治疗模式和生存结局：来自 I-O Optimise 计划的回顾性分析。
BMC Pulm Med. 2020 Sep 10;20(1):240. doi: 10.1186/s12890-020-01270-z.
8
Immunotherapy for NSCLC With Brain Metastases: What Can We Learn From Real-World Data?非小细胞肺癌脑转移的免疫治疗：我们能从真实世界数据中学到什么？
J Thorac Oncol. 2019 Jul;14(7):1119-1121. doi: 10.1016/j.jtho.2019.03.013.
9
Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.新型全身治疗药物的应用：晚期非小细胞肺癌成人患者的真实世界模式。
Cancer Treat Res Commun. 2023;36:100730. doi: 10.1016/j.ctarc.2023.100730. Epub 2023 Jun 14.
10
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.胸部恶性肿瘤的新兴疗法——免疫疗法、靶向治疗和非小细胞肺癌中的 T 细胞疗法。
Surg Oncol Clin N Am. 2020 Oct;29(4):555-569. doi: 10.1016/j.soc.2020.06.009. Epub 2020 Jul 29.
引用本文的文献
1
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.外部对照臂：新冠疫情揭示了在临床和公共卫生调查中实时使用真实世界证据的优点。
Front Med (Lausanne). 2023 Jul 6;10:1198088. doi: 10.3389/fmed.2023.1198088. eCollection 2023.
2
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.中国非小细胞肺癌中PD-L1表达与临床病理及基因组特征的相关性
J Oncol. 2022 Apr 11;2022:1763778. doi: 10.1155/2022/1763778. eCollection 2022.
3
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.用于恶性胸膜间皮瘤的免疫检查点抑制剂：一项法国多中心回顾性真实世界研究。
Cancers (Basel). 2022 Mar 15;14(6):1498. doi: 10.3390/cancers14061498.
4
Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis.免疫检查点抑制剂在真实世界中治疗晚期非小细胞肺癌患者的有效性和安全性：综述与荟萃分析
Cancers (Basel). 2021 Mar 19;13(6):1388. doi: 10.3390/cancers13061388.
5
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.曲妥珠单抗和 T-DM1 引入前后 HER2 阳性晚期乳腺癌的生存情况：SONABRE 登记研究。
Breast Cancer Res Treat. 2021 Jul;188(2):571-581. doi: 10.1007/s10549-021-06178-8. Epub 2021 Mar 20.
本文引用的文献
1
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.评估晚期非小细胞肺癌免疫治疗患者结局的真实世界终点的探索性分析
JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.
2
Real-world Evidence-What Does It Really Mean?真实世界证据——它究竟意味着什么？
JAMA Oncol. 2019 Jun 1;5(6):781-783. doi: 10.1001/jamaoncol.2019.0450.
3
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
4
Pembrolizumab plus Chemotherapy in Lung Cancer.帕博利珠单抗联合化疗治疗肺癌
N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567.
5
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.基线类固醇对非小细胞肺癌患者程序性细胞死亡-1 和程序性死亡配体 1 阻断疗效的影响。
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.
6
Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.用于评估药物安全性和有效性的真实世界证据与真实世界数据。
JAMA. 2018 Sep 4;320(9):867-868. doi: 10.1001/jama.2018.10136.
7
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
8
What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews.什么是真实世界数据？基于文献和利益相关者访谈的定义综述。
Value Health. 2017 Jul-Aug;20(7):858-865. doi: 10.1016/j.jval.2017.03.008. Epub 2017 May 11.
9
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
10
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
Zotero 插件